	US 12,221,629 B2
	Methods for producing fibroadipogenic progenitor cells
Michael S. Kyba, Minneapolis, MN (US); Natalya Goloviznina, Minneapolis, MN (US); Ning Xie, Minneapolis, MN (US); and Abhijit Dandapat, Lexington, MA (US)
Assigned to REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Filed by REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Filed on Jun. 14, 2021, as Appl. No. 17/346,948.
Claims priority of provisional application 63/039,847, filed on Jun. 16, 2020.
Prior Publication US 2021/0388321 A1, Dec. 16, 2021
Int. Cl. C12N 5/077 (2010.01); A61K 35/34 (2015.01); A61P 21/00 (2006.01); G01N 1/30 (2006.01); G01N 33/569 (2006.01)

CPC C12N 5/0658 (2013.01) [A61K 35/34 (2013.01); A61P 21/00 (2018.01); C12N 5/0653 (2013.01); C12N 5/0656 (2013.01); G01N 1/30 (2013.01); G01N 33/56966 (2013.01); C12N 2501/599 (2013.01); C12N 2506/13 (2013.01); G01N 2001/302 (2013.01); G01N 2333/70596 (2013.01)]

15 Claims

1. A method of producing a preparation of fibroadipogenic progenitors (FAPs), comprising:

contacting a cell mixture comprising FAPs with an anti-CD73 agent having affinity for CD73, wherein the agent has an optional tag, and

separating the anti-CD73 agent labeled cells from the cell mixture to produce the preparation of FAPs,

wherein the cell mixture is not contacted with an additional positive co-staining selection agent,

wherein the cell mixture is dissociated from a human skeletal muscle tissue sample comprising FAPs,

wherein the cell mixture is not cultured under culturing conditions prior to contacting with the anti-CD73 agent, and

wherein myogenic cells are excluded by contacting the cell mixture with the anti-CD73 agent and separating the anti-CD73 agent labeled cells from the cell mixture.